Hang Ta specialises in novel solutions for diagnosis and treatment of life-threatening diseases such as cardiovascular and cancerous diseases

Dr. Hang Ta researches nanosensors for detecting and grading diseasesMolecular imaging/Diagnosis of cardiovascular diseaseNovel nanomaterials for theranostics of cardiovascular, inflammatory and cancerous diseasesNovel reversible blood clotting agent.

​Dr. Hang Ta is an Australian National Health and Medical Research Council (NHMRC) ECR Fellow at Australian Institute for Bioengineering and Nanotechnology, the University of Queensland. She got her Bachelor degree in Chemical Engineering and Food Technology, a Masters degree in Biotechnology and a PhD in Drug Delivery. During her research career, she has been awarded many prizes, grants and prestigious fellowships such as National Heart Foundation and NHMRC ECR fellowships. Her research addresses solutions for current problems in diagnosis and treatment of diseases. She has published papers in journals with medium-to-high impact factor such as Nature Protocols (Jif: 13.47), Circulation Research (Jif: 11.861), Biomaterials (Jif: 8.496) and Journal of Controlled Release (Jif: 8.078). Her research was highlighted on cover page of Circulation Research, a second-ranked journal in the field of cardiovascular research. Dr Hang Ta has successfully attained more than $900,000 funding in the form of grants, fellowships, scholarships and travel awards. She is also a peer reviewer for various scientific journals.

Industry Engagement and Collaborations

​Dr Hang Ta has established strong collaborations with national and international experts from Baker IDI Heart and Diabetes Institute, Monash University, University of Melbourne, University of Wollongong, and Soochow University (China).

Key Publications

​Christoph E. Hagemeyer, Karen Alt, Angus P. R. Johnston, Georgina K. Such, Hang T. Ta, Melissa K. M. Leung, Sandeep Prabhu, Xiaowei Wang, Frank Caruso, Karlheinz Peter. 2015. Particle Generation, Functionalization and Sortase A-mediated Modification with Targeting Antibodies for Diagnostic and Therapeutic Use. Nature Protocol, 10, 90-105. Jif = 11.74.

Hang T. Ta; Sandeep Prabhu; Ephraem Leitner; Fu Jia; D. von Elverfeldt; K. Putnam; T. Heidt; A. Nair; H. Pearce; C. von zur Muhlen; X. Wang; K. Peter; C.E. Hagemeyer. 2011. Enzymatic Single-chain Antibody Tagging: A Universal Approach to Targeted Molecular Imaging and Cell Homing in Cardiovascular Disease. Circulation Research, 109, 365-373. Jif = 11.861.
(Second ranked journal in Cardiovascular Research field. One image from the publication was selected for the cover of the August 5th issue of Circulation Research. The article was also highlighted on cover page of the journal).

Hang T. Ta, Crispin R. Dass, Ian Larson, Peter Choong, Dave E. Dunstan. 2009. A hydrogel delivery system for osteosarcoma gene therapy with pigment epithelium-derived factor. Biomaterials, 30, 4815-4823. Jif = 8.496.

Hang T. Ta, Crispin R. Dass, Ian Larson, Peter Choong, Dave E. Dunstan. 2009. A chitosan-dipotassium orthophosphate hydrogel for the delivery of doxorubicin in the treatment of osteosarcoma. Biomaterials, 30, 3605–3613. Jif = 8.496.Hang T. Ta, Crispin R. Dass, Dave E. Dusntan. 2008. Injectable chitosan hydrogels for localised cancer therapy. Journal of Controlled Release, 126, 205-216. Jif = 8.078.

Full list of publications available at UQ eSpace

Funding

​Dr Hang Ta has successfully attained more than $900,000 funding in the form of grants, fellowships, scholarships and travel awards from NHMRC, National Heart Foundation, Baker IDI Heart and Diabetes Institute, University of Melbourne, University of Queensland, and CASS Foundation.